english

Programme des séminaires externes de l'IRCM

Lieu : IRCM, salle de conférences, bâtiment 3, rez-de-chaussée

Contact : charles.theillet@inserm.fr
Téléphone : 04 67 61 37 66

Mercredi 20 Juin 2018, 14h00

Giulio Preta

 

Life Science Center, Vilnius University, Lithuania

 

'Targeting lipid rafts as a strategy against infection and cancer"

 

Short summary of the work: 

Lipid rafts are membrane micro-domains that are enriched in cholesterol, sphingomyelin, sphingolipids and phospholipids. Their importance for living cells is underlined by their involvement in many processes including bacterial and viral entry, cardiovascular and prion diseases as well as cancer. Targeting lipid rafts is emerging as an innovative strategy to limit bacterial or viral infection and to increase the sensitivity to apoptosis of different types of tumours. Behind well-known cholesterol depleting agents (cyclodextrin) new compounds involved in cholesterol homeostasis were recently discovered. These potential drug candidates are capable to modify the lipid rafts composition and to alter the signalling platform associated with them.  Multiple technologies including confocal microscopy to visualize lipid rafts, viability assays to determine the toxic effect of compounds on the cells, offer the opportunity to study in details the changes induced by this new class of cholesterol-targeting agents.

Vendredi 22 Juin 2018, 14h00

Jérôme Déjardin

 

IGH, CNRS, Montpellier 

 

"Atypical heterochromatin stimulates alternative lengthening of telomeres"

 

Contact: claude.sardet@inserm.fr

Vendredi 29 Juin 2018, 14h00

Daniel Fisher

 

IGMM, CNRS Montpellier

 

"Not just a proliferation marker: Ki-67 promotes carcinogenesis by organising the nucleus to promote cellular plasticity"

 

Contact: charles.theillet@inserm.fr

Vendredi 6 Juillet 2018, 14h00

Fanny Jaulin, 

 

INSERM-U981 Institut Gustave Roussy, Villejuif.

 

"Collective epithelial-based metastases in colorectal carcinoma patients"

 

As a critical step in cancer progression and a challenge to patient treatment, tumour cell dissemination has been the subject of intense investigation across a range of model systems, in vitro and in animals. These studies have led to the assumption that the fatal progression of carcinoma is associated with a loss of epithelial architecture and polarity1-3 as single tumour cells escape from the primary tumour to reach secondary sites4,5. However, these studies have been performed using experimental model systems and the mechanisms driving metastatic spread in cancer patients remain under-investigated. Here, we collected and monitored over 50 patient specimens ex vivo to investigate the cell biology of colorectal cancer (CRC) metastasis as it spreads to the peritoneum. This reveals a new mode of cancer dissemination. Large clusters of cancer epithelial cells displaying an inverted apico-basolateral polarity, which we term Tumour Spheres with Inverted Polarity (TSIPs), were observed throughout the process of tumour dissemination. We show that TSIPs form and propagate through the collective apical budding of hyper-methylated neoplastic tissues. Despite their inverted topology, TSIPs collectively invade extracellular matrices, paired patients¹ peritoneum explants and initiate metastases in mice xenograft models. Further, the presence of TSIPs in peritoneal effusions correlates with metastases burden and adverse patient prognosis. Thus, despite their having a robust epithelial architecture, TSIPs appear to drive the peritoneal dissemination of CRC, as well as other primary cancers, such as breast carcinoma.  By applying cell biological methods to live primary cancer specimens, we provide an alternative conception of cancer dissemination that goes against the prevailing consensus and could not be anticipated from experimental model systems.

 

Contact: charles.theillet@inserm.fr

Vendredi 13 Juillet 2018, 14H

Franck Vandemoere, 

 

IGF, CNRS UMR5203, INSERM U1191, Montpellier

 

"Regulation by phosphorylation of two GPCRs targeted by antipsychotics"

 

Contact: pierre.martineau@inserm.fr

Jeudi 6 Sept. 2018, 14h

Cristina Muller et  Nicholas van der Meulen 

Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Zürich, Suisse

 

"Preclinical development and application using exotic radionuclides"

 

contact: jean-pierre.pouget@inserm.fr

Vendredi 7 Septembre 2018, 14h00

Joffrey Pelletier

 

IDIBELL, Barcelone

 

“Targeting GMP synthesis reveals a hierarchy of p53-cell cycle checkpoints in CRCs”

 

Contact: laurent.lecam@inserm.fr

Vendredi 21 Septembre 2018, 14h00

Eric Soler

 

IGMM, CNRS Montpellier

 

“Chromatin looping as a regulator of normal and pathological erythropoiesis”

 

Contacteric.julien@inserm.fr

Vendredi 12 Octobre 2018, 14h00

Chann Lagadec

 

Cell Plasticity and Cancer, INSERM U908, Université de Lille

 

“Reborn from fire, or how non-cancer stem cells reprogram as CSC under radiation-induced inflammatory chemokines stimulation”

 

the work summed up:

Cancer stem cell (CSC) identification in solid and hematologic tumors has paved the way to many fundamental and translational studies. However, recent studies have depicted the presence of cancer stem cell plasticity. Indeed, differentiated breast cancer cells (non-CSCs) can generate iCSCs (induced CSCs) in response to various stimuli. Nevertheless, reprogramming mechanisms remain unknown, and strategies to reduce the reprogramming of non-CSCs into iCSCs might prevent treatment-resilient cancer cells driving recurrences. We demonstrated, for the first time, that chemokines are involved in reprogramming and can be used to target radiation-induced CSC enrichment. In combination with radiation treatment, inhibition of these chemokines allows increased survival of mice in xenograft model. We also demonstrated that the expression of chemokines and their receptors is associated with CSC profiles in tumor patients. More interestingly, expression of specific chemokines or their receptors could be useful as prediction markers. We are actually investigating intracellular mechanisms driving anti-cancer treatments-induced reprogramming. Also, we are developing the first animal transgenic model to track and distinguish CSCs from iCSCs, and so to study in vivo reprogramming.

 

Contactcharles.theillet@inserm.fr

Lundi 19 Novembre 2018, 14h00

Arnaud Mourier

 

PhD, Institut de Biochimie et de Génétique Cellulaires, Bordeaux

 

"An unexpected link between mitochondrial dynamics and energy metabolism”

 

Contactlaurent.lecam@inserm.fr

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés